Previous close | 5.61 |
Open | 5.85 |
Bid | 0.00 x 0 |
Ask | 5.77 x 100 |
Day's range | 5.72 - 5.85 |
52-week range | 4.08 - 6.53 |
Volume | |
Avg. volume | 21,339 |
Market cap | 329.932M |
Beta (5Y monthly) | 0.24 |
PE ratio (TTM) | 38.27 |
EPS (TTM) | 0.15 |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.00 |
Revenues for First Quarter of 2024 were $37.7 Million, Representing a 23% Increase Year-over-YearFirst Quarter 2024 Adjusted EBITDA of $7.5 Million, Representing a 96% Increase Year-over-YearMomentum Primarily Driven by U.S. Sales of the Company’s Two Most Significant Catalysts, KEDRAB® and CYTOGAM®Strong First Quarter Results and Positive Outlook for Remainder of 2024 Support Increase of Full-Year Revenue Guidance to $158 Million-$162 Million and Adjusted EBITDA to $28 Million-$32 Million Confe
REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2024, prior to the open of the U.S. financial markets on Wednesday, May 8, 2024. Kamada management will host an
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript March 6, 2024 Kamada Ltd. beats earnings expectations. Reported EPS is $0.09, expectations were $0.05. KMDA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to Kamada Ltd.’s Fourth Quarter and […]